General Information of Drug (ID: DM9201K)

Drug Name
F-652 Drug Info
Indication
Disease Entry ICD 11 Status REF
Graft-versus-host disease 4B24 Phase 2 [1]
Cross-matching ID
TTD Drug ID
DM9201K

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting Interleukin-22 (IL22)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fezakinumab DMJX2P4 Psoriasis vulgaris EA90 Phase 2 [3]
RG7880 DM452RF Diabetic foot ulcer BD54 Phase 2 [4]
ILV-095 DMQ01MP Psoriasis vulgaris EA90 Phase 1 [3]

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Interleukin-22 (IL22) TTLDX4N IL22_HUMAN Agonist [2]

References

1 ClinicalTrials.gov (NCT02406651) A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT). U.S.National Institutes of Health.
2 An Open-Label, Dose-Escalation Study to Assess the Safety and Efficacy of IL-22 Agonist F-652 in Patients With Alcohol-associated Hepatitis. Hepatology. 2020 Aug;72(2):441-453.
3 Emerging Therapies for the Treatment of Psoriasis. Dermatol Ther (Heidelb) 2012 December; 2(1): 16.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)